ClinicalTrials.gg
RecruitingNCT06312956MULTI-OSASUpdated Sep 9, 2025

Multidimensional Evaluation of Patients' Affected by Obstructive Apnea Syndrome (OSAS) Before and After Ventilotherapy

An observational study in Obstructive Sleep Apnea, Sleep Disorder and Well-Being, Psychological, sponsored by Istituto Auxologico Italiano. Recruiting at 1 site in Italy. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Istituto Auxologico Italiano · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
65
Ages
20 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Sleep Apnea, Obstructive with a site in Italy — 9 open to participants now, 10 under way, none of them phase 3. Sleep Apnea, Obstructive · Italy.

Planned enrollment
8th of 10
65 · median 70
Started
2024
with 1 other
Observational
10 of 29
6 open now
Registered
20th of 29
by date
Lead sponsor
6 of 29
Istituto Auxologico Italiano

Among the 29 studies in Sleep Apnea, Obstructive with a site in Italy, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2024, is one of 10 observational ones, and was the 20th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

9 of the 29 studies in Sleep Apnea, Obstructive with a site in Italy are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 20 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Sleep Apnea, Obstructive with a site in Italy, or all of them as a file.
02

Study summary

This observational study aims to evaluate multiple dimensions of health in patients with Obstructive Sleep Apnea Syndrome (OSAS), before and after three weeks of ventilotherapy.

Specifically, the study aims to identify pre- vs post-treatment differences in the following domains:

  • cognitive performance
  • blood expression of biomarkers related to neurodegeneration
  • psychosocial wellbeing

Thus, patients will complete the following evaluations before (T0) and after (T1) ventilotherapy:

  • neuropsychological standard assessment
  • blood sampling
  • psychosocial self-reported questionnaires
Read the detailed description

Obstructive Sleep Apnea Syndrome is associated with cognitive difficulties, low psychosocial wellbeing and quality of life; however, the possible beneficial contribution of ventilotherapy on these dimensions is not completely clear. Ventilotherapy restores brain oxygenation and improve rest, possibly increasing cognitive performances, psychosocial health and quality of life. Multidisciplinary approaches to the treatment of OSAS are rare, although recommended. Solid proof of OSAS comorbidities may encourage clinicians to adopt a holistic perspective of care, leading to better rehabilitative outcomes. Also, evidence of the beneficial effects of ventilotherapy could increase patients' compliance to ventilotherapy, which is generally low.

The study aims to evaluate multiple dimensions of patient's health before and after three weeks of ventilotherapy, focusing on the cognitive performance, the blood expression of biomarkers related to neurodegeneration, and individual's psychosocial wellbeing.

Overall, it is expected improved cognitive performances and psychosocial wellbeing after ventilotherapy. Also, a reduction in the blood expression of biomarkers related to neurodegeneration (if found before the treatment) is hypothesized, although the limited research in this field requires cautious predictions.

Comprehensive evidence about OSAS comorbidity, beyond breath and sleep difficulties, is mandatory to design innovative multidisciplinary rehabilitative approaches in line with a holistic perspective of care. Effective multidisciplinary approaches are considered the gold standard in medical care, leading to better treatment outcomes and higher patients' satisfaction.

Beyond the clear ethical implication of providing higher quality of treatment, multidisciplinary interventions also imply a shared responsibility of treatment, preventing from clinical misjudgments and professionals' burnout.

03

Conditions studied

  • Obstructive Sleep Apnea
  • Sleep Disorder
  • Well-Being, Psychological
  • Cognitive Impairment
  • Cognitive Change
  • Neurologic Signs
04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individual affected by OSAS

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • OSAS diagnosis (AHI > 5)
  • handedness: right

Exclusion criteria

Exclusion Criteria:

  • previous ventilotherapy
  • neurological and/or neurodegenerative conditions
  • Personality disorders, autism spectrum disorders, schizophrenia, psychosis
  • sleep disorders comorbidities (eg., narcolepsy)
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
65 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • DeviceContinuous Positive Airway Pressure Ventilotherapy

    Breathing support device during sleeping

    Also known as: CPAP

06

What researchers measure

Primary outcomes

  1. Overall cognitive functioning

    Montreal Cognitive Assessment MoCA (score range: 0-30; higher scores indicate higher cognitive functioning)

    Time frame: baseline and after 3 weeks

  2. Selective attention

    Multiple Features Target Cancellation (MFTC) test (accuracy score range from 0 to 1; higher score suggest better performance)

    Time frame: baseline and after 3 weeks

  3. Memory and learning

    Selective Reminding Test - SRT: three scores are provided. 1) long term memory storage capacity (0-72), learning (0-72), delayed recall (0-12). Higher scores indicate better performance.

    Time frame: baseline and after 3 weeks

  4. Visuo-spatial abilities

    Rey Figure - copy: test score range from 0 to 36, higher scores indicate better performance

    Time frame: baseline and after 3 weeks

  5. Inhibition

    Stroop Test: higher time scores and error scores indicate worst inhibitory control

    Time frame: baseline and after 3 weeks

  6. Planning

    Tower of London - ToL: higher time score ( 0-36) and accuracy score (0-36) indicate better performance

    Time frame: baseline and after 3 weeks

  7. Decision making

    Balloon Analog Risk Task - BART (test score)

    Time frame: baseline and after 3 weeks

Secondary outcomes

  1. biomarkers of neurodegeneration

    blood concentration (pg/ml)

    Time frame: baseline and after 3 weeks

  2. psychosocial wellbeing and satisfaction

    Psychological General Well-Being Index (i.e., test scores)

    Time frame: baseline and after 3 weeks

  3. Quality of life (perceived psycho-physical and socio-economic wellbeing and satisfaction)

    Quality of Life Scale: 16-items self-report scored from 1 - terrible to 7 - delighted (score range 16-112); higher score indicate higher wellbeing and satisfaction.

    Time frame: baseline and after 3 weeks

07

Study locations

1 of 1 sites recruiting
  • IRCCS Istituto Auxologico Italiano
    Piancavallo, VCO 28824, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Jun 2026, 28 months after the start.

Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 28 months is close to that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2024
First posted
Mar 15, 2024
StartActual
Feb 29, 2024
Primary completionEst.
Jun 2026
CompletionEst.
Dec 2026
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06312956
Responsible party
Sponsor
First posted
Mar 15, 2024
Start date
Feb 29, 2024
Primary completion
Jun 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 9, 2025

Study contacts

Sofia Tagini, PhD
Contact
s.tagini@auxologico.it
00393339915288

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion